Humira, adalimumab
Named-patient access overview. Humira is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions.
Ask about Humira
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Humira
Humira is the brand name for adalimumab, a fully human monoclonal antibody manufactured by AbbVie. The US Food and Drug Administration first approved Humira in December 2002 for rheumatoid arthritis. Over 20+ years it became one of the most-prescribed biologics in the world, with the broadest label of any anti-TNF agent and a deep evidence base across rheumatology, gastroenterology, dermatology, and ophthalmology.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Humira lost US biosimilar exclusivity in 2023, and multiple adalimumab biosimilars are now on the US market. The originator Humira remains available, and many treating physicians and patients prefer to stay on the originator molecule when continuity of clinical response matters. Biosimilar substitution rules vary by destination country and by payer.
Mechanism of action
Tumor necrosis factor alpha, or TNF-α, is a master inflammatory cytokine. In autoimmune disease, TNF-α drives joint destruction, gut inflammation, skin plaque formation, and abscess cycles. Adalimumab binds TNF-α directly and prevents it from docking onto its receptors on immune cells. The downstream inflammatory cascade is interrupted.
In plain terms: TNF-α is a megaphone the misfiring immune system uses to amplify itself. Humira pulls the megaphone out of its hand.
FDA-approved indications
The Humira label is unusually broad. Approved US indications include rheumatoid arthritis, juvenile idiopathic arthritis (age 2 and older), psoriatic arthritis, ankylosing spondylitis, Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), plaque psoriasis, hidradenitis suppurativa (age 12 and older), and non-infectious intermediate, posterior, and panuveitis. Age-appropriate indications differ between presentations. Patients should always confirm the current label and the indication that matches their case with their treating physician.
Dosing and administration
Humira is administered as a subcutaneous injection from a prefilled syringe or autoinjector pen. The most common adult regimen is 40 mg every other week. Some indications (Crohn's disease, ulcerative colitis, hidradenitis suppurativa) require a loading regimen of 160 mg at week 0, 80 mg at week 2, then 40 mg every other week starting week 4. Weekly dosing is used in some pediatric and hidradenitis populations. Refrigerated storage between 36 and 46 degrees Fahrenheit is required, with limited room-temperature stability. Self-injection at home is the norm after physician training.
Side-effect profile
The most commonly reported side effects are injection-site reactions, upper respiratory infections, headache, and rash. As an anti-TNF agent, Humira carries a boxed warning for serious infections (including tuberculosis reactivation, invasive fungal infections, and bacterial sepsis) and for malignancies (including lymphoma and other cancers, with a specific signal for hepatosplenic T-cell lymphoma in young patients with inflammatory bowel disease).
Tuberculosis screening before initiation is standard of care. Live vaccines should be avoided while on therapy. Patients with active or chronic hepatitis B, demyelinating disease, congestive heart failure, or active malignancy require careful evaluation before starting. Long-term monitoring and infection vigilance are routine. The right monitoring cadence is always a conversation between patient and treating physician.
Why international patients seek Humira cross-border
Many of the markets Reserve Meds serves have local Humira availability that is either limited to a narrow set of indications, reserved for hospital-only dispensing, or supplied through programs with multi-month waitlists and rationing. Patients with hidradenitis suppurativa, uveitis, pediatric Crohn's, or hidradenitis suppurativa in adolescents frequently find no local route at all, even with a clean US-label indication and a treating physician's prescription.
Some patients also prefer the originator molecule when a stable response on US-sourced Humira is at risk of being disturbed by an involuntary local switch to a biosimilar. Reserve Meds sources Humira from a US-licensed pharmaceutical wholesale partner, with full serialization and unbroken cold chain from US warehouse to destination. Every case starts with the treating doctor's prescription, is documented, and routed through the destination country's lawful import framework. We do not handle controlled substances. We do not sell direct to consumers.
Start a request for Humira
Send us the medicine and your country. We reply within one business day with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote.
Access by country
Reserve Meds publishes a detailed country deep-dive for Humira in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list adalimumab as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Frequently asked questions
How can I get Humira if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Humira for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Humira through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Humira. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Humira through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Humira to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Humira to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Humira cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Humira?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.